IGC Pharma, Inc. (SWB:IGS1) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of shares of common stock Announced: about US$234,000 · US$0.3 a share Use of proceeds: Working capital and general corporate purposes, including continued funding of the Phase 2 clinical program for IGC-AD1 | Jan 5, 2026 |
| Private placements and at-the-market offering Closed: US$3.5M raised | Aug 19, 2025 |
| Private placement of common shares Announced: about US$475,000 Buyers: Frank Zaccanelli; Robert K. Coughlin; Joseph H. Mangan Use of proceeds: General corporate purposes and advancing the CALMA Phase 2 clinical trial on agitation in Alzheimer's disease | Apr 24, 2025 |